FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:522-523 January 29, 2009 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ibrahim, H. N. PubMed Citation

Kidney transplantation remains the preferred therapeutic option for patients with end-stage renal disease (ESRD), since survival and health-related quality of life are better after kidney transplantation than after dialysis therapy. The incidence of ESRD has risen steadily over the past several decades, in part because of the increased incidence of diabetes, obesity, and hypertension, alone or in combination, and in part owing to improved care for concurrent health risks such as ischemic heart disease and stroke. Moreover, the number of patients with ESRD who receive treatment has also increased because of a more liberal acceptance of candidates for dialysis therapy.¹ . . . [Full Text of this Article]

Source Information

From the Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.